PLRX supply chain intelligence for Pliant Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Pliant Therapeutics, Inc. (PLRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev… |
| AZN | AstraZeneca PLC | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| BCAX | Bicara Therapeutics Inc. | 72% | Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In additi… |
| BCAX | Bicara Therapeutics Inc. | 72% | duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials … |
| CELG-RI | CELG-RI | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate… |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials … |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In additi… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PLRX graph: health technology assessment. Risks R… |
| JNJ | Johnson & Johnson | 72% | health technology assessment. Risks Related to Our Intellectual Property • Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our p… |
| MRK | Merck & Co., Inc. | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev… |
| NKTR | Nektar Therapeutics | 72% | health technology assessment. Risks Related to Our Intellectual Property • Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our p… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR g… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | aring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate rev… |
| AZN | AstraZeneca PLC | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| BCAX | Bicara Therapeutics Inc. | 72% | duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials … |
| BCAX | Bicara Therapeutics Inc. | 72% | Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX g… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PLRX graph: approval of our product candi… |
| CELG-RI | CELG-RI | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large scale manufacturing for clinical trials … |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 72% | Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from CRBP graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from CRBP g… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from MRK grap… |
| MRK | Merck & Co., Inc. | 72% | approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from PLRX graph: pearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical t… |
| NVSEF | Novartis AG | 72% | pearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. … |
| ABBVIE-INC-BICARA-THERAPEUTICS-INC-INCYTE-CORPOR | ABBVIE-INC-BICARA-THERAPEUTICS-INC-INCYTE-CORPOR | 62% | product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks associated with large scale manufacturing for clinical trials … |
| BIOMEDICAL-RESEARCH-INC | BIOMEDICAL-RESEARCH-INC | 62% | terially from those expressed or implied by forward-looking statements. See "Special Note Regarding Forward-Looking Statements" elsewhere in this Report. RISK FACTORS Risks Related to Our Financial P… |
| COMPUTERSHARE-TRUST-COMPANY | COMPUTERSHARE-TRUST-COMPANY | 62% | olicies There have been no significant changes to the accounting policies during the three months ended March 31, 2026, as compared to the significant accounting policies described in Note 2 of the "… |
| CONDENSED-FINANCIAL-STATEMENTS-PLIANT-THERAPEUTI | CONDENSED-FINANCIAL-STATEMENTS-PLIANT-THERAPEUTI | 62% | rice or a positive health technology assessment. Risks Related to Our Intellectual Property • Our success depends in part on our ability to protect our intellectual property. It is difficult and cost… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | third-party research and development expense by product candidate or preclinical program. These expenses primarily relate to outside consultants, clinical research organizations and contract manufact… |
| OXFORD-FINANCE-LLC | OXFORD-FINANCE-LLC | 62% | third-party research and development expense by product candidate or preclinical program. These expenses primarily relate to outside consultants, clinical research organizations and contract manufact… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PLRX-DEBT | Debt stack $28.8M | 90% | Market cache reports total debt of $28.8M. |
| PLRX-DEBT-11805 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PLRX-OWNER-TANG-CAPITAL-MANAGEMENT-LLC | TANG CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists TANG CAPITAL MANAGEMENT LLC as top holder; 93 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PYXS | Pyxis Oncology, Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 2 | ['supplier'] |
| BNTX | BioNTech SE | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| GSK | GSK plc | 100.00 | 2 | |
| MRK | Merck & Co., Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NKTR | Nektar Therapeutics | 100.00 | 1 | ['supplier'] |
| NVSEF | Novartis AG | 100.00 | 1 | ['customer', 'supplier'] |
| GNMSF | Genmab A/S | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | ['customer', 'supplier'] |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| DKS | DICK'S Sporting Goods, Inc. | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| ZTS | Zoetis Inc. | 50.00 | 2 | |
| EXOZ | eXoZymes, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| BHC | Bausch Health Companies Inc. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 |